Business Context and Reporting Period
Company: enVVeno Medical Corporation (NVNO)
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2025
Reporting Period: Event date of October 30, 2025
The Company, incorporated in Delaware and headquartered in Irvine, California, reported the entry into a material definitive agreement to establish an equity financing program.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a potential capital raise.
- Maximum Offering Size: Up to $50,000,000 of common stock.
- Commission Rate: 3% of gross proceeds payable to the sales agent.
- Underlying Registration: Shares will be issued pursuant to a previously filed Form S-3 (File No. 333-273546) declared effective on August 23, 2023.
Material Changes
On October 30, 2025, the Company entered into an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc. as the sales agent. This agreement enables the Company to sell shares of its common stock from time to time through ordinary brokers' transactions on the NASDAQ Capital Market or other markets at prevailing market prices.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company has no obligation to sell any shares under the agreement and retains the right to suspend offers or terminate the agreement at any time. The filing includes a Prospectus Supplement filed with the SEC on the same date.
Risks and Contingencies:
- Sales are subject to market conditions and the Company's discretion.
- The agreement includes customary indemnification and contribution rights for the agent.
- The Company will reimburse the agent for certain specified expenses.
- Offers are not valid in states where registration or qualification is required prior to sale.
Investor Verification Checklist
- Verify the current market price of NVNO common stock to assess potential dilution impact from a $50 million ATM program.
- Review the filed Prospectus Supplement (Exhibit 10.1) for specific terms regarding the 3% commission and expense reimbursements.
- Confirm the Company's current cash position and burn rate to determine the urgency of utilizing this ATM facility.
- Check for any subsequent filings indicating the actual commencement of share sales under this agreement.